ArticleEuropean journal of nuclear medicine and molecular imaging2021
Comparison of the diagnostic performance and impact on management of 18F-FDG PET/CT and whole-body MRI in multiple myeloma.
Article in European journal of nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- ESR Essentials: bone marrow MRI in oncology-practice recommendations by the European Society of Musculoskeletal Radiology.European radiology · 2026Guideline
- EANM guidelines on the use of [European journal of nuclear medicine and molecular imaging · 2024Guideline
- Association of loss of spleen visualization on whole-body diffusion-weighted imaging with prognosis and tumor burden in patients with multiple myeloma.Scientific reports · 2021Trial
- Fifteen years of use of functional imaging in multiple myeloma: where we started and where we are going.Blood advances · 2025Review
- Bone disease burden does not impact overall survival in newly diagnosed patients with multiple myeloma - a single center, retrospective imaging analysis on 119 patients.Journal of bone oncology · 2025Article
- Qualitative and Quantitative Inter-Observer Agreement of Multiparametric Whole-Body MRI in Staging and Follow-Up of Myeloma Patients.Diagnostics (Basel, Switzerland) · 2025Article
- Whole body MRI by MY-RADS for imaging response assessment in multiple myeloma.Blood cancer journal · 2025Observational
- Diagnostic Innovations: Advances in imaging techniques for diagnosis and follow-up of multiple myeloma.Journal of bone oncology · 2025Review
- Yearly Assessment of Bone Disease in Patients with Asymptomatic Multiple Myeloma Identifies Early Progression Events and Should Be the Standard Clinical Practice.Journal of clinical medicine · 2025Article
- Role of Imaging in Multiple Myeloma: A Potential Opportunity for Quantitative Imaging and Radiomics?Cancers · 2024Review
- Chemokine Receptor 4-Targeted PET/CT with [Molecular imaging and biology · 2024Article
- Review
- National myeloma patient survey shows continuing inappropriate imaging and geographical inequalities.The British journal of radiology · 2024Article
- New Developments in Myeloma Treatment and Response Assessment.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Hybrid simultaneous whole-body 2-[European radiology · 2023Article
- [Positron emission tomography/computed tomography (PET/CT) in multiple myeloma].Der Radiologe · 2022Review
- Prospective Evaluation of Whole-Body MRI versus FDG PET/CT for Lesion Detection in Participants with Myeloma.Radiology. Imaging cancer · 2021Observational
- Comparison of [Diagnostics (Basel, Switzerland) · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
purposeComparative data on the impact of imaging on management is lacking for multiple myeloma. This study compared the diagnostic performance and impact on management of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) and whole-body magnetic resonance imaging (WBMRI) in treatment-naive myeloma.
methodsForty-six patients undergoing 18F-FDG PET/CT and WBMRI were reviewed by a nuclear medicine physician and radiologist, respectively, for the presence of myeloma bone disease. Blinded clinical and imaging data were reviewed by two haematologists in consensus and management recorded following clinical data ± 18F-FDG PET/CT or WBMRI. Bone disease was defined using International Myeloma Working Group (IMWG) criteria and a clinical reference standard. Per-patient sensitivity for lesion detection was established. McNemar test compared management based on clinical assessment ± 18F-FDG PET/CT or WBMRI.
resultsSensitivity for bone lesions was 69.6% (32/46) for 18F-FDG PET/CT (54.3% (25/46) for PET component alone) and 91.3% (42/46) for WBMRI. 27/46 (58.7%) of cases were concordant. In 19/46 patients (41.3%) WBMRI detected more focal bone lesions than 18F-FDG PET/CT. Based on clinical data alone, 32/46 (69.6%) patients would have been treated. Addition of 18F-FDG PET/CT to clinical data increased this to 40/46 (87.0%) patients (p = 0.02); and WBMRI to clinical data to 43/46 (93.5%) patients (p = 0.002). The difference in treatment decisions was not statistically significant between 18F-FDG PET/CT and WBMRI (p = 0.08).
conclusionCompared to 18F-FDG PET/CT, WBMRI had a higher per patient sensitivity for bone disease. However, treatment decisions were not statistically different and either modality would be appropriate in initial staging, depending on local availability and expertise.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.